In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sosei R&D Ltd.

Division of Sosei Co. Ltd./Sosei R&D Ltd./Sirus Pharmaceuticals Ltd.
www.arakis.com

Latest From Sosei R&D Ltd.

EU's CHMP Gives Green Light To Three New Products And A New Indication For Afinitor

The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.

BioPharmaceutical Europe

Acacia Pharma Ltd.

Acacia Pharma is focused on supportive care, primarily cancer supportive care. It has established a discovery approach generating product opportunities that have a high probability of success, based on known drugs--new indications, optimized formulations, and optimal isomers. Its lead product, for post-operative nausea and vomiting, has been widely marketed for another indication and can be differentiated through delivery.
BioPharmaceutical

Innovation: Defined by the Customer, Not by Pharma

All drug company executives agree that innovation is the answer to the industry's woes-R&D productivity, pricing, perception, the lot. But they differ on what innovation means.
BioPharmaceutical Strategy

Trade Sales Trump IPOs, Even for Platforms

Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Arakis Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Sosei Co. Ltd.
  • Sosei Heptares
  • Senior Management
  • Ken Cunningham, CEO
    Peter Keen, CFO
    Robin Bannister, PhD, Dir., R&D
  • Contact Info
  • Sosei R&D Ltd.
    Phone: (44) 1799 532350
    Chesterford Research Park
    Little Chesterford, CB10 1XL
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register